Therapeutic Plasma Exchange And COVID-19: A Rapid Review

Abstract

Since it was first reported by the China Center for Disease Control and Prevention (China CDC) in December 2019, multiple mechanisms of pathogenesis have been implied in the morbidity and mortality associated with COVID the Severe Acute Respirato- ry Coronavirus-2 (SARS-CoV-2). Therapeutic Plasma Exchange (TPE), was early used as a treatment alternative for COVID19. After the publication of some initial studies the US Food and Drug Ad- ministration, granted Emergency Use Authorization (EUA), and the World Health Organization (WHO) has endorsed it as potentially ef- ficacious therapy for severe critically ill patients. We describe our experience with TPE and examine ongoing trials. We base recom- mendations on the current available data to provide a guide and rec- ommendations on the treatment and potentially effects of TPE for patients with COVID-19.